Table 1 In-vitro VEGFR-2 inhibition assay.

From: Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact

Compound

VEGFR-2 IC50 (nM)

4a

169.40 ± 7.40

4b

132.05 ± 5.70

4c

253.60 ± 11.00

4d

61.04 ± 2.60

4e

112.17 ± 4.80

4f

83.35 ± 3.70

4g

99.76 ± 4.30

4h

217.36 ± 9.40

4i

287.50 ± 13.00

4j

368.16 ± 16.00

Sorafenib

51.41 ± 2.30

  1. IC50 values are the mean ± S.D (standard deviations) of three experiments.
Back to article page